Clearmind completes recruitment for first alcohol use disorder cohort in CMND-100 Phase I/IIa trial
CMND•Clearmind Medicine completed recruitment for the first alcohol use disorder cohort in its Phase I/IIa trial of CMND-100. Part B will assess safety, tolerability and potential reductions in alcohol craving among patients with moderate-to-severe disease.
1. Trial cohort recruited
Clearmind Medicine completed recruitment for the first alcohol use disorder cohort in its Phase I/IIa trial of CMND-100. Part B will evaluate patients with moderate-to-severe disease, assessing safety, tolerability and potential reductions in alcohol craving. The study follows completed testing in healthy volunteers, for which safety and tolerability data have been reported; Part B will generate the first clinical results in patients with alcohol use disorder.
